Retrospective cohort study to examine the association between serum amylase and the incidence of type 2 diabetes mellitus, Toranomon Hospital Health Management Center Study 23 (TOPICS 23)
Authors' conclusion
Results showed that not low but previously decreased serum amylase was a risk factor for T2DM, suggesting the significance of periodic examinations of serum amylase values to detect individuals at high risk of T2DM.
Study context
- Population
- Individuals with annual health examinations for 6 years (7 times) at the Toranomon Hospital Health Management Center6,917 analysed
- Participants
- 8,316 individuals
- Exposure
- Low (Q1) vs higher (Q2–Q5) serum amylase level at entry, and decreased (Q1) vs higher (Q2–Q5) annual change rate of amylase
- Outcome
- Incident T2D
Methodological detailssingle-centre health examination cohort
- Single-centre health examination cohort
Main finding
As reported in the abstract
Estimate (95% CI)
Amylase ≤57 IU/L (Q1)vs Amylase ≥58 IU/L (Q2-Q5)Cox regression
aHR 0.97(0.84–1.13)
Annual change ≤−2.0% (Q1)vs Annual change ≥−1.9% (Q2-Q5)logistic regression
aOR 3.53(3.00–4.16)
- Incident T2D after the first year
- 1021 patients
Observational data: associations, not effects.
Further findings
Sensitivity analyses (baseline amylase; combination of age, BMI and HbA1c)
- Adjusted ORs consistently significant throughout sensitivity analyses
Original publication
Retrospective cohort study to examine the association between serum amylase and the incidence of type 2 diabetes mellitus, Toranomon Hospital Health Management Center Study 23 (TOPICS 23). BMJ Open Diabetes Res Care. Published 12 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →